DHR
Danaher Corporation
NYSE · Healthcare · Medical - Diagnostics & Research · US
$207.27
−1.78%Year over year
Reported trailing growth
- Revenue
- +4.6%
- EBITDA
- +5.9%
- EBIT
- -0.8%
- EPS
- +19.5%
- Free cash flow
- +12.4%
- Operating cash flow
- +7.6%
Forward estimates
Based on analyst estimates
- Revenue
- +9.8%
- EBITDA
- +32.5%
- EPS
- +56.5%
Three-year CAGR
- Revenue
- -2.7%
- EBITDA
- -9.9%
- EBIT
- -12.0%
- Net income
- -20.6%
- EPS
- -19.7%
- Free cash flow
- -10.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026